Celladon Corporation (CLDN) 1.15 $CLDN Celladon Sets

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celladon Corporation (CLDN) 1.15 $CLDN

Celladon Sets Date for Special Meeting of Stockholders
GlobeNewswire - Wed Feb 10, 3:57PM CST
Celladon Corporation (Nasdaq:CLDN) announced today it has set a date for a special meeting of its stockholders to vote on matters related to the proposed merger with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)

Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO
GlobeNewswire - Fri Nov 20, 6:05AM CST
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a biopharmaceutical company committed to improving or preserving the sight of people suffering from serious eye diseases with an unmet medical need, today announced the appointment of Paul B. Cleveland to chief executive officer (CEO) and to the Board of Directors effective December 9. He also will serve as principal financial officer of Avalanche on an interim basis. Mr. Cleveland, previously the chief executive officer of Celladon Corporation, brings more than 20 years of leadership experience to Avalanche, including management and operational experience across the biotechnology industry. This includes positions at multiple public biotechnology companies, including CEO, president, chief financial officer and Board member as well as chief operating officer at a venture capital firm. Subsequent to December 9, Hans P. Hull who has been serving as interim CEO of Avalanche since July, will return to his previous role of senior vice president of business operations.
CLDN: 1.15 (-0.02), AAVL: 4.14 (-0.18)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Eiger BioPharmaceuticals, Inc. - CLDN
ACCESSWIRE - Thu Nov 19, 4:36PM CST
NEW YORK, NY / ACCESSWIRE / November 19, 2015 / The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)

CELLADON ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Launches an Investigation into the Proposed Merger of Celladon Corporation; Are Celladon Shareholders Getting a Fair Deal?
BusinessWire - Thu Nov 19, 8:45AM CST
Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Celladon Corporation (NASDAQ: CLDN) breached their fiduciary duties in connection with the proposed merger of the Company with Eiger BioPharmaceuticals, Inc.
CLDN: 1.15 (-0.02)

72-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of August 31, 2015 Lead Plaintiff Deadline in the Class Action Lawsuit Against Celladon Corp.
BusinessWire - Fri Aug 28, 7:58PM CDT
Law Offices of Howard G. Smith reminds investors of the August 31,2015 lead plaintiff deadline in the class action lawsuit filed on behalf of a class comprising purchasers of the securities of Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Investors with losses of over $100,000 are encouraged to contact Howard G. Smith, Esq. to discuss their legal rights.
CLDN: 1.15 (-0.02)

August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Aug 25, 8:55AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed against Celladon Corp over alleged Securities Laws Violations and that a deadline is upcoming on August 31, 2015 for investors with a substantial investment in (NASDAQ:CLDN) shares between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Celladon Corporation of Class Action Lawsuit and Upcoming Deadline - CLDN
GlobeNewswire - Mon Aug 24, 7:00AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN) and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
CLDN: 1.15 (-0.02)

SECURITIES ALERT: The Rosen Law Firm Reminds Celladon Corporation Investors of the Important August 31, 2015 Deadline in the Class Action -- CLDN
GlobeNewswire - Fri Aug 21, 5:04PM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of Celladon Corporation (NASDAQ:CLDN) common stock from July 7, 2014 through June 25, 2015, all dates inclusive, of the important August 31, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celladon Corporation and Lead Plaintiff Deadline August 31, 2015
GlobeNewswire - Thu Aug 20, 9:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corporation ("Celladon" or the "Company" (Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015 inclusive. (the "Class Period" .
CLDN: 1.15 (-0.02)

GPM Announces the Filing of a Securities Class Action on Behalf of Celladon Corp. Investors
BusinessWire - Wed Aug 19, 3:48PM CDT
Glancy Prongay & Murray LLP ("GPM" announces the filing of a class action lawsuit on behalf of investors of Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN), who purchased shares between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" . Celladon investors have until August 31, 2015 to file a motion to serve as lead plaintiff in the class action.
CLDN: 1.15 (-0.02)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015
BusinessWire - Mon Aug 17, 1:51PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)

Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 12.07 (-0.02), CNAT: 1.81 (-0.07), CLDN: 1.15 (-0.02), LLY: 77.75 (-0.02), CLSN: 1.24 (-0.01), ASND: 18.44 (+0.34), ABBV: 64.10 (-0.06), ANAC: 99.06 (-0.14), ARNA: 1.55 (-0.02)

Celladon Reports Second Quarter 2015 Financial Results
GlobeNewswire - Tue Aug 11, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), today announced financial results for the quarter ended June 30, 2015 and recent corporate updates.
CLDN: 1.15 (-0.02)

CELLADON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Celladon Corporation To Contact The Firm
PR Newswire - Tue Aug 11, 3:00PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Celladon Corporation ("Celladon" or the "Company" (NASDAQ:CLDN) of the August 31, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Celladon and certain officers. The lawsuit has been filed in the United States District Court for the Southern District of California, on behalf of a class consisting of all persons or entities who purchased Celladon securities between July 7, 2014 and June 25, 2015 (the "Class Period" .
CLDN: 1.15 (-0.02)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Celladon Corporation and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
GlobeNewswire - Mon Aug 10, 10:18AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Celladon Corporation (NASDAQ:CLDN) securities between July 7, 2014 and June 25, 2015.
CLDN: 1.15 (-0.02)

Global Arteriovenous Fistula Clinical Trials Review, H1, 2015 - Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kcqk26/arteriovenous) has announced the addition of the "Arteriovenous Fistula Global Clinical Trials Review, H1, 2015" report to their offering. Arteriovenous Fistula Global Clinical Trials Review, H1, 2015 provides data on the Arteriovenous Fistula clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Arteriovenous Fistula. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Arteriovenous Fistula. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Shire Plc - Proteon Therapeutics, Inc. - CYATHUS EXQUIRERE Pharmaforschungs GmbH - Celladon Corporation Clinical Trial Overview of Top Institutes / Government - California Institute of Renal Research - Capital Medical University - City Hospitals Sunderland NHS Foundation Trust - Department of Health, UK - Duke University - Emory University - Englewood Hospital and Medical Center - Japan Interventional Radiology in Oncology Study Group - National Cheng-Kung University Hospital - NHS Greater Glasgow and Clyde For more information visit http://www.researchandmarkets.com/research/kc...eriovenous
SHPG: 187.18 (-3.04), CLDN: 1.15 (-0.02), PRTO: 8.82 (-0.90)

SECURITIES ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Celladon Corporation -- CLDN
GlobeNewswire - Fri Jul 31, 5:10PM CDT
The Rosen Law Firm, a global investor rights firm, announces that a class action lawsuit has been filed on behalf of purchasers of Celladon Corporation (NASDAQ:CLDN) securities from July 7, 2014 through June 25, 2015, all dates inclusive. The lawsuit seeks to recover damages for Celladon investors under the federal securities laws.
CLDN: 1.15 (-0.02)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of August 31, 2015 - CLDN
PR Newswire - Thu Jul 30, 1:03PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CLDN: 1.15 (-0.02)

Morgan & Morgan Reminds Investors That Class Action Lawsuits Have Been Filed Against Celladon Corporation -- CLDN
GlobeNewswire - Thu Jul 30, 12:31PM CDT
Morgan & Morgan reminds investors that securities class actions have been filed in the United States District Court for the Southern District of California on behalf of those who purchased shares of Celladon Corp. ("Celladon" or the "Company" (Nasdaq:CLDN), during the period between July 7, 2014 and June 25, 2015, inclusive (the "Class Period" .
CLDN: 1.15 (-0.02)

Lifshitz & Miller Law Firm Announces Investigation of Celladon Corporation, Edison International, Inc., Louisiana Bancorp, Inc., Navient Corp., On Deck Capital, Inc., Thoratec, and Vivint Solar
PR Newswire - Fri Jul 24, 6:47PM CDT
Celladon Corporation
ONDK: 6.33 (-0.06), THOR: 63.50 (+0.05), CLDN: 1.15 (-0.02), VSLR: 3.18 (+0.03), LABC: 24.36 (+0.08), NAVI: 14.38 (-0.03), EIX: 72.72 (+0.76)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocuphire Pharma Faces Scrutiny Over Shareholder Obligations

Updated Category News Views 81

Ocuphire Pharma Under Investigation by Ademi LLP Recently, there have been growing concerns regarding the fiduciary responsibilities of Ocuphire Pharma, Inc. (NASDAQ: OCUP) to its public shareholders. Ademi LLP has initiated an investigation focused on whether the company is adequately protecting the interests of its shareholders amidst its dealings with Opus Genetics....

Continue Reading
Investigation Into Shareholder Claims Against AMLX, FIVE, HUM, and VSTS

Updated Category News Views 190

Grabar Law Office Investigates Shareholders' Rights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Vestis Corp. (NYSE: VSTS) shareholders may have claims worth exploring. Grabar Law Office wants to inform these shareholders about the ongoing investigations into potential securities fraud that could have affected...

Continue Reading
Investors Seek Recovery in Class Action Against Paragon 28, Inc.

Updated Category News Views 109

Class Action Lawsuit Filed for Paragon 28, Inc. Investors We are reaching out to inform investors about an important class action securities lawsuit involving Paragon 28, Inc. This initiative aims to recover losses for investors who may have been adversely affected by purported securities fraud associated with the company. Details of the Class Action The class action...

Continue Reading
Alto Ingredients, Inc. Announcement for Q2 2025 Results

Updated Category News Views 165

Alto Ingredients, Inc. to Announce Second Quarter Financial Results Alto Ingredients, Inc. (NASDAQ: ALTO), a prominent producer and distributor of specialty alcohols and renewable fuels, is set to release its financial results for the second quarter of 2025. This announcement will take place after the market closes on Wednesday, August 6, 2025. Conference Call Details...

Continue Reading
Phare Bio Secures $27 Million to Revolutionize Antibiotic Discovery

Updated Category News Views 226

Phare Bio scored big back in 2024 with up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H). This isn’t just pocket change; it’s a lifeline aimed at supercharging their generative artificial intelligence (AI) platform. Teaming up with MIT's Collins Lab and Harvard's Wyss Institute, they set their sights on developing new classes...

Continue Reading